Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

CAR-T

11th Jun 2025

Plain language summary: Examining how loncastuximab tesirine performs after CAR T-cell treatment for diffuse large B-cell lymphoma in everyday practice

11th Jun 2025

Real-world results of sequential loncastuximab and CAR T-cell therapy in large B-cell lymphoma: plain language summary

15th Aug 2024

Plain language summary of the CARTITUDE-4 study on ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma

This is a summary of a clinical study called CARTITUDE-1. This study tested the anti-cancer chimeric antigen receptor-T cell (CAR-T ) therapy ciltacabtagene autoleucel, abbreviated as cilta-cel, in people with multiple myeloma, a cancer that affects a specific type of blood cell called plasma cells. The participants in this study had relapsed or refractory disease, which means that their cancer did not improve or returned after 3 or more previous anti-cancer treatments.
11th Jul 2023

Plain Language Summary: the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy